Lauer B, Stahl F, Bratanow S, Schuler G
Klinik für Innere Medizin/Kardiologie, Herzzentrum, Universität Leipzig.
Herz. 2000 Sep;25(6):557-63. doi: 10.1007/pl00001968.
In patients with severe angina pectoris due to coronary artery disease, who are not candidates for either percutaneous coronary angioplasty or coronary artery bypass surgery, transmyocardial laser revascularization (TMR) often leads to improvement of clinical symptoms and increased exercise capacity. One drawback of TMR is the need for surgical thoracotomy in order to gain access to the epicardial surface of the heart. Therefore, a catheter-based system has been developed, which allows creation of laser channels into the myocardium from the left ventricular cavity. Between January 1997 and November 1999, this "percutaneous myocardial laser revascularization" (PMR) has been performed in 101 patients at the Herzzentrum Leipzig. In 63 patients, only 1 region of the heart (anterior, lateral, inferior or septal) was treated with PMR, in 38 patients 2 or 3 regions were treated in 1 session. There were 12.3 +/- 4.5 (range 4 to 22) channels/region created into the myocardium. After 3 months, the majority of patients reported significant improvement of clinical symptoms (CCS class at baseline: 3.3 +/- 0.4, after 6 months: 1.6 +/- 0.8) (p < 0.001) and an increased exercise capacity (baseline: 397 +/- 125 s, after 6 months: 540 +/- 190 s) (p < 0.05). After 2 years, the majority of patients had experienced sustained clinical benefit after PMR, the CCS class after 2 years was 1.3 +/- 0.7, exercise capacity was 500 +/- 193 s. However, thallium scintigraphy failed to show increased perfusion in the PMR treated regions. The pathophysiologic mechanisms of myocardial laser revascularization is not yet understood. Most of the laser channels are found occluded after various time intervals after intervention. Other possible mechanisms include myocardial denervation or angioneogenesis after laser revascularization, however, unequivocal evidence for these theories is not yet available. In conclusion, PMR seems to be a safe and feasible new therapeutic option for patients with refractory angina pectoris due to end-stage coronary artery disease. The first results indicate improvement of clinical symptoms and increased exercise capacity, whereas evidence of increased perfusion after laser revascularization in the laser-treated regions is still lacking.
对于因冠状动脉疾病导致严重心绞痛且不适合进行经皮冠状动脉腔内血管成形术或冠状动脉旁路移植术的患者,心肌激光血运重建术(TMR)通常可改善临床症状并提高运动能力。TMR的一个缺点是需要进行开胸手术才能接触到心脏的心外膜表面。因此,已开发出一种基于导管的系统,该系统可从左心室腔向心肌内创建激光通道。1997年1月至1999年11月期间,莱比锡心脏中心对101例患者进行了这种“经皮心肌激光血运重建术”(PMR)。在63例患者中,仅对心脏的1个区域(前壁、侧壁、下壁或间隔)进行了PMR治疗,在38例患者中,在1次治疗中对2个或3个区域进行了治疗。心肌内每个区域创建了12.3±4.5(范围4至22)个通道。3个月后,大多数患者报告临床症状有显著改善(基线时加拿大心血管学会分级:3.3±0.4,6个月后:1.6±0.8)(p<0.001),运动能力提高(基线:397±125秒,6个月后:540±190秒)(p<0.05)。2年后,大多数患者在PMR后仍有持续的临床获益,2年后加拿大心血管学会分级为1.3±0.7,运动能力为500±193秒。然而,铊闪烁扫描未能显示PMR治疗区域的灌注增加。心肌激光血运重建术的病理生理机制尚不清楚。在干预后的不同时间间隔后,发现大多数激光通道闭塞。其他可能的机制包括激光血运重建术后心肌去神经支配或血管生成,然而,这些理论的确切证据尚不存在。总之,PMR似乎是终末期冠状动脉疾病导致的顽固性心绞痛患者一种安全可行的新治疗选择。初步结果表明临床症状改善且运动能力提高,而激光治疗区域激光血运重建术后灌注增加的证据仍然缺乏。